Overcoming the economies of scale paradigm
The NevoLine™ biomanufacturing platform proposes a disruptive approach to achieve cost-effective viral production.
The technology combines principles of process intensification, chaining, and automation in self-contained modules to drastically reduce facility footprint, capital, and operational expenditures. The NevoLine platform offers solutions for various applications such as viral vaccines, gene therapies, and oncolytic viruses.
WATCH & LISTEN
Reinventing commercial-scale virus production
The low footprint NevoLine platform delivers large quantities of bulk product, rapidly building cost-effective capacity for viral production.
The platform is suited for GMP-compliant manufacture from clinical to commercial scale.
CLICK & LEARN
An intensified & integrated modular approach to virus manufacture
Automated procedures simplify the day-to-day operations and decrease the number of manual interventions, reducing labor costs while promoting process reliability.
Unit operations located in functionally closed systems with air classification and biosafety levels that are tailored to the selected application, enhancing product sterility and personnel safety.
Independent modules are chained together to provide product-specific platforms for clinical and commercial-scale viral manufacture.
Delivering large manufacturing capacities within a small footprint, drastically reducing capital and operational expenditures
Automated operations increasing reproducibility, in high-safety modules offering application-specific biosafety levels
Building production capacity in new or existing facility for a rapid market access